Filipe, da S., , Hughes, J., Aranday-Cortes, E., Irving, W., Foster, G., … Thomson, E. (2018). Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2017.11.044 (Original work published 2018)

Levin, M., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., … Study, G. P. (2022). Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. The New England Journal of Medicine, 386(23), 2188-2200. https://doi.org/10.1056/NEJMoa2116620 (Original work published 2022)